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Hsp90 chaperones stabilize many tyrosine kinases includ-
ing several oncogenes, which are inhibited or induced to
degrade by the Hsp90 inhibitor geldanamycin (GA). As a
consequence, GA has been developed for future che-
motherapeutic use in several tumour types including
neuroblastoma (NB). Alternative splicing of the neuro-
trophin receptor tyrosine kinase TrkA may have a pivotal
function in regulating NB behaviour, with reports
suggesting that tumour-suppressing signals from TrkA
may be converted to oncogenic signals by stress-regulated
alternative TrkAIII splicing. Within this context, it is
important to know whether Hsp90 interacts with TrkA
variants in NB cells and how GA inﬂuences this. Here, we
report that both TrkAI and TrkAIII are Hsp90 clients in
human NB cells. TrkAI exhibits GA-sensitive interaction
with Hsp90 required for receptor endoplasmic reticulum
export, maturation, cell surface stabilization and ligand-
mediated activation, whereas TrkAIII exhibits GA-
sensitive interactions with Hsp90 required for spontaneous
activity and to a lesser extent stability. We show that
GA inhibits proliferation and induces apoptosis of TrkAI
expressing NB cells, whereas TrkAIII reduces the
sensitivity of NB cells to GA-induced elimination. Our
data suggest that GA-sensitive interactions with Hsp90
are critical for both TrkAI tumour suppressor and
TrkAIII oncogenic function in NB and that TrkAIII
expression exerts a negative impact on GA-induced NB
cell eradication, which can be counteracted by a novel
TrkAIII-speciﬁc peptide nucleic acid inhibitor.
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Introduction
The Hsp90 family is comprised of abundant cytoplasmic
ATPases Hsp90a and Hsp90b and the endoplasmic
reticulum (ER) paralogue Grp94 (Richter et al., 2001;
Rosser et al., 2004; Frey et al., 2007). These chaperones
have essential functions in the folding, maturation,
activity and stability of numerous client proteins,
including many protein tyrosine kinases (Neckers,
2002; Citri et al., 2006). The essential function of
Hsp90 in stabilizing client proteins is reﬂected by
induction of client protein degradation by the speciﬁc
Hsp90 inhibitor ansamycin antibiotic geldanamycin
(GA). This quinone occupies the N-terminal ATP/
ADP-binding site of Hsp90 homodimers, abrogating
ATP/ADP binding, inhibiting ATPase activity and
interfering with ATPase-dependent client–protein inter-
actions (Grenert et al., 1997, 1999; Onuoha et al., 2007),
which frequently results in client–protein dissociation
and ubiquitin-dependent degradation (Schneider et al.,
1996; Stebbins et al., 1997; Connell et al., 2001; Xu et al.,
2002; Zhou et al., 2003). Hsp90 proteins also exhibit
generalized passive chaperone function with some client
proteins, involving an alternative ATP/ADP-indepen-
dent-binding site (Shankovich et al., 1992; Jakob et al.,
1995; Scheibel et al., 1998).
Hsp90 clients include the oncogenic kinases ErbB2
(Her2/neu), EGFRvIII, BCR-ABL, Flt3, NPM-ALK,
PDGFRa, Src and Akt, which are either inhibited or
induced to degrade by GA (Xu et al., 2001, 2002;
Lavictoire et al., 2003; Zhou et al., 2003; Dai and
Whitesell, 2005; Matei et al., 2007). As a consequence,
GA has been evaluated and developed as a potential
chemotherapeutic agent and GA analogues have re-
cently completed Phase-I clinical trials in adult and
paediatric tumours and the paediatric tumour neuro-
blastoma (NB) identiﬁed for potential future GA-
analogue chemotherapy (Lo`pez-Maderuelo et al., 2001;
Kim et al., 2003; Escobar et al., 2005; Graner and
Bigner, 2005; Grem et al., 2005; Bagatell et al., 2007;
Erdmann et al., 2007; Ramanathan et al., 2007; Shen
et al., 2007; Solit et al., 2007; Weigel et al., 2007; Xu and
Neckers, 2007).
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NBs represent the most frequent paediatric extra-
cranial solid tumour and originate from neural crest
cells during sympathetic nervous system development
(reviewed in Pahlman and Hedborg, 2000). Consistent
with this origin, NBs exhibit varying degrees of
neurotrophin tyrosine kinase receptor TrkA expression,
which regulates sympathetic nervous system develop-
ment (Pahlman and Hedborg, 2000; Orike et al., 2001).
TrkA expression in NB is considered to be clinically
relevant and unveils a pivotal function for this receptor
in regulating tumour behaviour (Nakagawara et al.,
1992; Nakagawara, 2001). TrkA is expressed as either
TrkAI, TrkAII or alternative TrkAIII splice variants
(Tacconelli et al., 2006). TrkAI and TrkAII differ in
exon 9 inclusion, are expressed as cell surface receptors
and activated on nerve growth factor (NGF) or NT3
neurotrophin ligation. In contrast, the stress-regulated
alternative TrkAIII splice variant bears a unique in-
frame exons 6/7 deletion, which abrogates receptor cell
surface expression and promotes intracellular accumula-
tion and spontaneous activation (Tacconelli et al., 2004,
2005, 2006). In NB, wild-type TrkA (I/II) is expressed
predominantly by low-stage tumours and exhibits
tumour-suppressor activity in NB models (Matsushima
and Bogenmann, 1990; Lavenius et al., 1995; Lucarelli
et al., 1997; Nakagawara, 2001; Eggert et al., 2002;
Tacconelli et al., 2004). In contrast, TrkAIII is expressed
by advanced stage tumours and exhibits oncogenic
activity in NB models (Tacconelli et al., 2004, 2005,
2006). This has led to the novel hypothesis that stress-
regulated alternative TrkAIII splicing provides a me-
chanism through which tumour-suppressing signals
from TrkAI may be converted to oncogenic signals
from TrkAIII during tumour progression, and has
identiﬁed TrkAIII as a novel potential therapeutic
target. Within this context and considering future GA
chemotherapeutic use, it is important to know how Hsp90
chaperones interact with alternative TrkA splice variants
and how GA inﬂuence this interaction in NB cells.
In this study, we report that both TrkAI and TrkAIII
are Hsp90 clients in human NB cells, involved in GA-
sensitive interactions potentially critical for TrkAI
tumour suppressor and TrkAIII oncogenic function.
We also show that TrkAIII exerts a negative impact on
GA-induced NB cell eradication that can be counter-
acted by a TrkAIII-speciﬁc peptide nucleic acid (PNA).
Results
GA and GA analogues destabilize cell surface TrkAI in
NB cells
TrkAI SH-SY5Y transfectants exhibited predominant
TrkAI localization to the cell surface and Golgi network
(GN), with GN localization conﬁrmed by overlapping
expression with the cis-GN marker GM130 (Figure 1a).
Overnight treatment with 1 mM GA induced complete
loss of cell surface TrkAI and increased intracellular
TrkAI accumulation that closely overlapped the ER
marker calnexin (Figure 1b). Immunoprecipitation (IP)–
western blots detected gp140TrkAI degradation at GA
concentrations X0.05 mM (Figure 1c), with complete
gp140TrkAI loss at GA concentrations X0.5 mM within
8 h (Figure 1d), associated with gp110TrkAI accumula-
tion (Figure 1c and d, data displayed for 0.1 mM GA
only). Co-treatment with 1 mM GA and 25 mM MG-132
abrogated gp140TrkAI degradation without inﬂuencing
gp110TrkA accumulation, indicating that GA had
induced lysosome/proteosome-mediated gp140TrkAI,
but not gp110TrkA degradation (Figure 1d). The
clinically relevant GA-analogues 17-AAG and 17-
DMAG (Miyata, 2005) also induced gp140TrkAI
degradation and promoted gp110TrkAI accumulation
in TrkAI SH-SY5Y transfectants at concentrations
X0.1 mM (Figure 1e, data displayed for 1 mM 17-AAG
and 1 mM 17-DMAG only). Furthermore, GA at
concentrations of 0.1 and 1 mM induced degradation of
endogenous gp140TrkA, but not gp110TrkA expressed
by non-transfected IMR-32 and SH-SY5Y NB cells
(Figure 1f), which was reversed by 25 mM MG132 in
IMR32 cells (Figure 1f) and also reduced cell surface
expression of endogenous TrkAI in IMR32 cells
(Figure 1g).
Pre-treatment of TrkAI SH-SY5Y transfectants for
30min with 1 mM GA, which did not reduce gp140TrkAI
levels, attenuated NGF-induced gp140TrkAI tyrosine
phosphorylation over a 30min time course, compared
with non-GA pre-treated NGF-activated controls
(Figure 2a, different TrkAI levels represent IP artefacts
and not differences in expression). Attenuation of
NGF-TrkAI activation after short-term GA pre-incuba-
tion was not reversed by 25 mM MG132, indicating
independence from lysosome/proteosome degradation
(Figure 2b). Overnight pre-treatment of TrkAI SH-SY5Y
Figure 1 GA induces degradation of cell surface gp140TrkAI. (a) Indirect IF demonstrating cell surface and GN-associated TrkAI
immunoreactivity and overlapping expression of intracellular TrkAI and GN-associated GM130 in TrkAI SH-SY5Y cells. (b) Indirect
IF demonstrating GA-induced loss of cell surface TrkAI associated with intracellular TrkAI accumulation, together with overlapping
with ER-associated calnexin, in TrkAI SH-SY5Y transfectants treated overnight with 1 mM GA. (c) IP–western blots demonstrating
GA-induced loss of gp140TrkAI, associated with gp110TrkAI accumulation in the absence of TrkAI tyrosine phosphorylation, in
TrkAI SH-SY5Y transfectants treated overnight with the GA concentrations indicated. (d) IP–western blot time course (0–24 h)
demonstrating loss of gp140TrkAI and accumulation of gp110TrkAI in TrkAI SH-SY5Y transfectants treated with 1mM GA in the
absence (upper panels) or presence (lower panels) of 25mM MGR132. Levels of a-tubulin (a-tub) in the whole extracts used for IP are
shown. (e) IP–western blots demonstrating loss of gp140TrkAI associated with gp110TrkAI accumulation in TrkAI SH-SY5Y
transfectants treated overnight with 1mM 17-AAG or 1mM 17-DMAG. (f) IP–western blots demonstrating GA-induced loss of
endogeous gp140TrkAI, but not endogenous gp110TrkAI or TrkAIII in non-transfected SH-SY5Y (left panels) and IMR-32 (right
panels) cells treated overnight with 0.1 and 1.0 mM GA for SH-SY5Y cell and 1 mM GA in the presence or absence of 25mM MG132 for
IMR-32 cells. (g) Indirect IF demonstrating the difference in TrkA immunoreactivity in IMR-32 cells treated overnight in the presence
or absence of 1mM GA.
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transfectants with 1 mM GA, which induced complete
gp140TrkAI loss, abrogated TrkAI responsiveness to
100 ng/ml NGF in terms of tyrosine phosphorylation
(Figure 2c). GA (1 mM) alone did not induce TrkAI
tyrosine phosphorylation (Figure 2d).
GA and GA analogues inhibit TrkAIII tyrosine
phosphorylation
TrkAIII SH-SY5Y transfectants treated overnight
with 1 mM GA exhibited less-centralized more diffuse
intracellular TrkAIII expression (Figure 3a). GA at
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concentrations of X0.05mM inhibited TrkAIII tyrosine
phosphorylation, with complete abrogation detected
within 2 h at GA concentrations X0.1mM (Figure 3b
and c), and reduced TrkAIII levels at GA concentrations
of X0.1mM (Figure 3b and c). Co-incubation with 1mM
GA and 25mM MG-132 reversed GA-induced TrkAIII –
loss, but failed to restore TrkAIII tyrosine phosphoryla-
tion (Figure 3c). TrkAIII exhibited re-phosphorylation
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Figure 2 GA inhibits TrkAI NGF responsiveness. (a) IP–western blots demonstrating relative attenuation of NGF-induced TrkAI
tyrosine phosphorylation (pTrkAI) in the absence of gp140TrkAI loss in TrkAI transfectants pre-treated for 30min with 1 mM GA,
followed by 100 ng/ml NGF for 0–30min, compared with non-GA pre-treated NGF-treated controls. (b) IP–western blots
demonstrating that MG132 (25mM) does not reverse GA-attenuated NGF-induced TrkAI tyrosine phosphorylation (pTrkAI) in TrkAI
transfectants pre-treated for 30min with 1 mM GA, compared with non-GA pre-treated NGF-treated controls. (c) IP–western blots
demonstrating induction of pg140TrkAI tyrosine phosphorylation (pTrkAI) by 100 ng/ml NGF in non-GA pre-treated TrkAI SH-
SY5Y transfectants, but not in TrkAI SH-SY5Y transfectants pre-treated overnight with 1mM GA, before treatment with 100 ng/ml
NGF, for the times indicated. (d) IP–western blots demonstrating total (TrkAI) and tyrosine phosphorylated TrkAI (pTrkAI) in
TrkAI SH-SY5Y transfectants treated with 100 ng/ml NGF (left panels) or 1mM GA (right panels) for the times indicated.
Figure 3 GA induces partial degradation of TrkAIII and inhibits TrkAIII tk activity. (a) Indirect IF demonstrating subtle changes in
intracellular TrkAIII immunoreactivity in TrkAIII SH-SY5Y transfectants treated overnight with 1 mM GA. (b) IP–western blots
demonstrating GA-induced loss of TrkAIII associated with inhibition of constitutive TrkAIII tyrosine phosphorylation in TrkAIII
SH-SY5Y transfectants treated overnight with GA, at the concentrations indicated. (c) IP–western blot time course (0–24 h)
demonstrating limited loss of TrkAIII and inhibition of TrkAIII tyrosine phosphorylation in TrkAIII SH-SY5Y transfectants treated
with 1mM GA, for the times indicated (upper panels) and reversal of TrkAIII loss, but not restoration of TrkAIII tyrosine
phosphorylation in TrkAIII SH-SY5Y transfectants co-treated with 1 mM GA and 25mM MG-132 (lower panels). (d) IP–western blots
demonstrating constitutive TrkAIII tyrosine phosphorylation in TrkAIII transfectants (lane 1), loss of TrkAIII tyrosine
phosphorylation after overnight treatment with 1 mM GA (lane 2) and restoration of TrkAIII tyrosine phosphorylation 8 h after
GA removal (lane 3). (e) IP–western blot time courses (0–24h) demonstrating: inhibition of TrkAIII tyrosine phosphorylation without
loss of total TrkAIII in TrkAIII SH-SY5Y transfectants treated overnight with 100 nM CEP-701 (upper panels); 1 mM GA-induced loss
of CEP-701-inhibited non-phosphorylated TrkAIII (middle panels) and reversal of this effect by 25 mM MG-132 (lower panels).
Constitutive TrkAIII tyrosine phosphorylated in untreated controls are presented for comparison (c) and relative a-tubulin levels
(a-tub) in the whole extracts used for IP shown. (f) IP–western blot time course (0–24h) demonstrating 1mM GA-induced loss
of muTrkAIII in stable SH-SY5Y transfectants in the absence of MG-132 (GA, upper panels) and reversal of this effect by 25mM MG132
(GA/MG-132, lower panels). (g) IP–western blots demonstrating limited loss of TrkAIII, associated with the abrogation of constitutive
TrkAIII tyrosine phosphorylation in TrkAIII SH-SY5Y transfectants treated overnight with 1mM 17-AAG or 1mM 17-DMAG.
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on GA removal (Figure 3d). MG-132 (25mM) alone did
not alter TrkAIII expression or constitutive tyrosine
phosphorylation in TrkAIII SH-SY5Y transfectants
(data not shown). GA (1mM) also induced low-level
degradation of non-phosphorylated CEP-701-inhibited
TrkAIII and muTrkAIII expressed by muTrkAIII stable
SH-SY5Y transfectants, which was reversed by 25mM
MG-132 (Figure 3e and f). CEP-701 (100nM) alone did
not induce TrkAIII loss (Figure 3e). GA-analogues 17-
AAG and 17-DMAG at concentrations of X1mM also
abrogated TrkAIII tyrosine phosphorylation and re-
duced TrkAIII levels (Figure 3g). Endogenous TrkAIII
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expressed by non-transfected SH-SY5Y and IMR-32 NB
cells was not reduced by overnight treatment with 1mM
GA (Figure 1g).
Pulse-chase analysis of GA effects on TrkAI and TrkAIII
Pulse-chase metabolic and biotin labelling of SH-SY5Y
transfectants conﬁrmed that gp140TrkAI matures from
nascent immature gp110TrkAI within 20min before cell
surface translocation within 1–2 h (Figure 4a). Pre-
treatment of TrkAI transfectants for 8 h with 1 mM GA
before pulse chase completely inhibited gp140TrkAI
maturation and cell surface translocation (Figure 4b).
Pulse-chase metabolic and biotin labelling of TrkAIII
SH-SY5Y transfectants conﬁrmed that nascent 100 kDa
TrkAIII neither matures further in molecular size nor
translocates to the cell surface (Figure 4c). Pre-treatment
of TrkAIII SH-SY5Y transfectants for 8 h with 1 mM
GA before pulse chase resulted in low-level TrkAIII
loss at times X1 h, associated appearance of a lower
molecular weight potential degradation product
(Figure 4d, arrow).
SH-SY5Y transfectants exhibit cell surface Hsp90
expression
Hsp90 interaction with gp140TrkAI at the cell surface
was supported by (a) FACS analysis, using a dual-
speciﬁc anti Hsp90a/b antibody, which detected cell
surface Hsp90 (a/b) expression in non-permeabilized
pcDNA, TrkAI and TrkAIII transfected SH-SY5Y
cells, reduced in TrkAI transfectants by siRNA
Hsp90a/b knockdown (Figure 5a); (b) siRNA Hsp90b,
but not Grp94 knockdown, which reduced cell surface
TrkAI expression in TrkAI SH-SY5Y transfectants
(Figure 5d); (c) gp140TrkAI co-IP of Hsp90 from
TrkAI SH-SY5Y transfectant membranes (Figure 5b)
and (d) overlapping cell surface Hsp90 (a/b) and TrkAI
expression in TrkAI SH-SY5Y transfectants (Figure 5c).
In contrast, TrkAIII SH-SY5Y transfectants exhibited
overlapping intracellular TrkAIII and Hsp90 (a/b)
expression (Figure 5c).
GA promotes TrkAI and TrkAIII ER retention and alters
interactions with Hsp90 and Grp78/BiP
GA-sensitive interactions between Hsp90 and TrkA
variants were conﬁrmed by GA-induced reduction in
TrkAI and TrkAIII co-IP of Hsp90, in whole cell
extracts, associated with GA-induced TrkAI binding
of Grp78/BiP and GA-increased TrkAIII binding of
Grp78/BiP (Figures 6a and 7a).
Within fractionated intracellular membranes, TrkAI
exhibited low levels of predominantly immature
gp110TrkAI within calnexin-positive ER membranes
and high levels of predominantly mature gp140TrkAI
within GM130, TGN46 and COP II positive, calnexin
negative, membranes of the ER Golgi-intermediate,
GN and COP vesicle compartments (Figure 6b and d).
TrkAI within ER membranes constitutively bound
Grp94 and calreticulin, but not Hsp90, Grp78/BiP or
calnexin, whereas TrkAI in non-ER membranes con-
stitutively bound Hsp90 (Figure 6d). Overnight
treatment with 1 mM GA promoted gp110TrkAI accu-
mulation within calnexin-positive ER membranes,
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Figure 4 Metabolic and biotin labelling of TrkAI and TrkAIII. Autoradiographs demonstrating (a) gp110–gp140kDa maturation of S35
pulse-labelled TrkAI and cell surface translocation of S35 and biotin-labelled mature gp140TrkAI in a 120min pulse-chase experimental
time course in TrkAI SH-SY5Y transfectants. (b) Inhibition of gp110–gp140kDa maturation of S35 pulse-labelled TrkAI and absence of
cell surface TrkAI translocation in TrkAI SH-SY5Y transfectants pre-incubated for 8 h with 1mM GA before metabolic labelling in a
120min pulse-chase experimental time course. (c) No change in S35 pulse-labelled TrkAIII molecular size and absence of cell surface
TrkAIII expression in TrkAIII SH-SY5Y transfectants in a 120min pulse-chase experimental time course. (d) Limited loss of
gp100TrkAIII in the absence of cell surface TrkAIII translocation in TrkAIII SH-SY5Y transfectants pre-treated for 8 h with 1mM GA
before a 120min pulse-chase experimental time course (the arrow indicates a potential GA-induced TrkAIII degradation product).
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Figure 5 TrkAI binds Hsp90a/b at the cell surface. (a) FACS analysis demonstrating cell surface Hsp90a/b expression in non-
permeabilized TrkAI SH-SY5Y transfectants (upper left panel); loss of cell surface Hsp90a/b expression in non-permeabilized TrkAI
SH-SY5Y transfectants after siRNA knockdown of Hsp90a and b (upper right panel) and cell surface Hsp90a/b expression in non-
permeabilized pcDNA (lower left panel) and TrkAIII SH-SY5Y transfectants (lower right panel). (b) IP–western blot demonstrating
TrkAI co-IP of Hsp90a/b from TrkAI SH-SY5Y cell membranes. (c) Indirect IF demonstration of overlapping cell surface Hsp90a/b
and TrkAI expression in TrkAI SH-SY5Y transfectants and overlapping intracellular Hsp90a/b and TrkAIII expression in TrkAIII
SH-SY5Y transfectants, with circled regions magniﬁed. (d) Indirect IF demonstrating loss of cell-surface TrkAI immunoreactivity in
TrkAI SH-SY5Y transfectants treated for 6 days with 1mM Hsp90b siRNA, but not Grp94 siRNA, compared with TrkAI SH-SY5Y
transfectants treated with transfection medium alone (control).
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Figure 6 GA induces ER retention of gp110TrkAI. (a) IP–western blots demonstrating the effect of GA on gp110 and gp140TrkAI
isoform expression and co-IP of Hsp90 and Grp78/BiP in whole cell extracts from untreated (Con) and 1 mM GA overnight-treated
(GA) TrkAI SH-SY5Y transfectants. (b, c) Western blots demonstrating the distribution of gp110 and gp140TrkAI, GM130, TGN46,
calnexin, COP I and COP II in Histodense ultracentrifugation-fractionated intracellular membranes puriﬁed from (b) untreated TrkAI
SH-SY5Y transfectants and (c) TrkAI SH-SY5Y transfectants treated overnight with 1mM GA. (d, e) IP–western blots demonstrating
the relative differences in the distribution of non-phosphorylated gp110 and gp140TrkAI and co-IP of Hsp90, Grp94, Grp78/BiP,
calnexin and calreticulin (calret) from Histodense ultracentrifugation-fractionated intracellular membranes puriﬁed from (d) untreated
TrkAI SH-SY5Y transfectants and (e) TrkAI SH-SY5Y transfectants treated overnight with 1 mM GA.
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associated with loss of Grp94 binding, induction of
Grp78/BiP binding and loss of TrkAI from non-ER
membranes (Figure 6c and e), but did not induce
re-distribution of calnexin, GM130, TGN46, COP I or
COP II (Figure 6c).
TrkAIII within internal membranes exhibited an
approximately equal steady state distribution between
calnexin-positive ER membranes and calnexin negative,
GM130, TGN46, COP I and COP II-positive ER
Golgi-intermediate compartment/GN/COP vesicle mem-
branes, within which TrkAIII also exhibited tyrosine
phosphorylation (Figure 7b and d). ER-associated
TrkAIII bound Hsp90, Grp78/Bip and calnexin in
addition to calreticulin and Grp94, and in non-ER
membranes bound Hsp90 and calreticulin (Figure 7d).
Overnight treatment with 1 mM GA increased ER
retention of non-phosphorylated TrkAIII, loss of
Hsp90 and Grp94 binding, and also increased Grp78/
BiP binding and TrkAIII loss from non-ER membranes
(Figure 7c and e).
SiRNA Hsp90 knockdown mimics GA
To further characterize Hsp90 interactions with TrkAI
and TrkAIII, speciﬁc Accell SMART Pool siRNAs were
used to knockdown Hsp90a, Hsp90b and Grp94
expression (four siRNAs per pool). Each gene-speciﬁc
siRNA induced maximal-speciﬁc knockdown of target
within 6 days (Figure 8a and b). In TrkAI transfectants,
siRNA Hsp90a and Hsp90b but not Grp-94 knockdown
induced gp140TrkAI loss and gp110TrkAI accumula-
tion (Figure 8a). In TrkAIII SH-SY5Y transfectants,
siRNA Hsp90b and Hsp90a but not Grp94 knockdown
inhibited constitutive TrkAIII tyrosine phosphorylation
and reduced TrkAIII levels (Figure 8b). Potential off-
target siRNA effects were ruled out by the speciﬁcity of
knockdown in the absence of co-lateral effects on the
other Hsp90 chaperones and a-tubulin, and by compar-
ison with siRNA Grp94 knockdown, which did not
inﬂuence TrkAI or TrkAIII expression (Figure 8a
and b).
TrkAIII tk-loop tyrosines and tk activity regulate
intracellular distribution
TrkAIII tk-loop tyrosine and tk-activity involvement in
determining TrkAIII intracellular distribution was
supported by comparing intracellular distribution of
non-mutated TrkAIII and non-phosphorylated tk-loop
tyrosine-mutated muTrkAIII (Figure 9a). muTrkAIII
exhibited greater ER retention than TrkAIII and bound
similar levels of Grp94, calnexin and 82 kDa Grp78/BiP,
but lower levels of Hsp90 (Figure 9b and c). Further-
more, overnight treatment of TrkAIII transfectants with
100 nM CEP-701 inhibited TrkAIII tyrosine phosphor-
ylation and augmented ER retention of non-phosphory-
lated TrkAIII, associated with reduced co-IP of Hsp90
(Figure 9d and e), whereas overnight treatment with
1mM sodium orthovanadate stimulated TrkAIII tyro-
sine phosphorylation and promoted TrkAIII re-distri-
bution to non-ER membranes, associated with increased
co-IP of Hsp90 (Figure 9d and e). TrkAI intracellular
distribution was not associated with receptor tyrosine
phosphorylation.
TrkAIII induces a partial ER-stress response
TrkAIII ER retention and constitutive Hsp90, Grp78/
Bip and calnexin binding indicates difﬁculty in over-
coming ER quality control and the possibility that
TrkAIII may induce ER stress. ER stress was assessed
by analysis of ATF6 transcription factor activation and
alternative XBP-1 transcription factor splicing (Schro-
der, 2008). ATF6 transcriptional factor activity, as-
sessed by reporter gene assay using the 5xATF6-GL3
construct (Wang et al., 2000), was signiﬁcantly increased
by 6.2-fold in TrkAIII SH-SY5Y transfectants com-
pared witho1-fold in pcDNA and TrkAI transfectants,
over luciferase activity from cfos-promoted enhancer-
less PoFLuc-GL3PGL3 (Po0.001 Student’ t-test)
(Figure 10a). Proteolytic ATF6 processing to its
50 kDa nuclear form was detected in TrkAIII, but not
pcDNA or TrkAI SH-SY5Y transfectants (Figure 10d,
arrow indicates processed ATF-6). TrkAIII transfec-
tants also exhibited higher constitutive expression of the
ER-stress chaperone Grp78/Bip, relative to a-tubulin
and Hsp90 protein expression, compared with pcDNA
and TrkAI transfectants (Figure 10b, d and e).
Constitutive alternative XBP-1 splicing was not detected
in either pcDNA, TrkAI or TrkAIII SH-SY5Y trans-
fectants (Figure 10c, lanes 0 h treatment with GA).
GA (1 mM) induced transient alternative XBP-1
splicing in pcDNA, TrkAI and TrkAIII transfectants
at 3 h, but no later (Figure 10c), reduced transcription
activity in 5xATF6PGL3 reporter gene assays and
inhibited ATF6 proteolytic processing from 3h onwards
in TrkAIII transfectants (Figure 10a and d), without
inﬂuencing ATF6 processing in pcDNA or TrkAI
transfectants (Figure 10d); increased Grp78/BiP expres-
sion in pcDNA and TrkAI transfectants to levels
expressed by TrkAIII SH-SY5Y transfectants within
9 h (Figure 10d and e) and induced Bcl-2 expression
exclusively in TrkAIII SH-SY5Y transfectants at 9 and
12 h (Figure 10d).
TrkAIII decreases SH-SY5Y GA-sensitivity
GA at concentrations of 0.1 mM (closed squares) and
1 mM (closed triangles) completely inhibited pcDNA and
TrkAI, but not TrkAIII SH-SY5Y transfectant prolif-
eration in 1, 2 and 3 days MTS assays (Figure 11a).
Transient TrkAIII expression for 4 days in pcDNA and
TrkAI SH-SY5Y stable transfectants signiﬁcantly re-
duced GA-induced elimination associated with low-level
proliferation in 2 and 3 days MTS assays (Po0.001 for
both transient TrkAIII transfectants at 2 and 3 days
versus sham transfected counterparts), but did not
signiﬁcantly alter proliferation in the absence of GA
(Figure 11b).
GA signiﬁcantly decreased 48 h survival of pcDNA
and TrkAI SH-SY5Y transfectant at concentrations
X0.1 mM, whereas TrkAIII SH-SY5Y transfectants
exhibited reduced 48 h survival at GA concentrations
of X1.0 mM (P>0.01, Student’s t-test) (Figure 11c). GA
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Figure 7 GA augments TrkAIII ER retention. (a) IP–western blots demonstrating relative changes in total and tyrosine
phosphorylated levels of TrkAIII (pTrkAIII) and TrkAIII co-IP of Hsp90 and Grp78/BiP in whole cell extracts from untreated
TrkAIII SH-SY5Y transfectants (Con) and TrkAIII SH-SY5Y transfectants treated overnight with 1mM GA. (b, c) Western blots
demonstrating the distribution of gp100TrkAIII, GM130, calnexin, TGN46, COP I and COP II in Histodense ultracentrifugation-
fractionated intracellular membranes puriﬁed from (b) untreated TrkAIII SH-SY5Y transfectants and (c) TrkAIII SH-SY5Y
transfectants treated overnight with 1 mM GA. (d, e) IP–western blots demonstrating relative changes in gp100TrkAIII levels, tyrosine
phosphorylated TrkAIII (pTrkAIII) and TrkAIII co-IP of Grp94, Hsp90a/b, Grp78/BiP, calreticulin (calret) and calnexin in
Histodense ultracentrifugation-fractionated intracellular membranes puriﬁed from (d) untreated TrkAIII SH-SY5Y transfectants and
(e) TrkAIII SH-SY5Y transfectants treated overnight with 1mM GA.
Hsp90 interacts with TrkAI and TrkAIII in neuroblastoma cells
AR Farina et al
4084
Oncogene
(0.1 mM) induced signiﬁcant apoptosis in pcDNA and
TrkAI (>50%, P>0.001, Student’s t-test), but not
TrkAIII transfectants (Figure 11d). Reduced GA
sensitivity of TrkAIII SH-SY5Y transfectant was not
associated with expression of the neuronal differentia-
tion markers NF-M and Neuro-D (data not displayed)
or morphological neuronal differentiation (this study;
Tacconelli et al., 2004). Speciﬁc knockdown of TrkAIII
expression by 7 days incubation of TrkAIII SH-SY5Y
transfectants with 10 mM TrkAIII-PNA, which did not
knockdown TrkAI expression in TrkAI transfectants
(Figure 11e), increased the sensitivity of TrkAIII
transfectants to GA-induced growth inhibition at
GA concentrationsX0.1 mM (Po0.001, Student’s t-test)
(Figure 11f).
In equal ratio TrkAI–TrkAIII SH-SY5Y transfectant
co-cultures (Figure 12a, left panel), 1 mM GA signiﬁ-
cantly reduced proliferation in 3 days MTS assays
(Po0.001, Student’s t-test) (Figure 12b), associated with
the elimination of TrkAI expressing cells (Figure 12a,
right panel), conﬁrmed by complete loss of TrkAI
mRNA and protein expression (Figure 12c and d).
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Figure 8 SiRNA knockdown of Hsp90 mimics the effect of GA on TrkAI and TrkAIII. RT–PCR demonstrating the effect of 3 days
incubation of (a) TrkAI SH-SY5Y transfectants and (b) TrkAIII SH-SY5Y transfectants with transfection medium alone (Con) or
1mM siRNAs speciﬁc for Grp94, Hsp90a and Hsp90b on mRNA expression of Grp94, Hsp90a, Hsp90b and GAPDH (upper 6 panels),
plus western blots (lower panels) demonstrating the effect of 6 days incubation of (a) TrkAI SH-SY5Y transfectants and (b) TrkAIII
SH-SY5Y transfectants with transfection medium (Con) or 1mM siRNAs speciﬁc for Grp94, Hsp90a or Hsp90b on Hsp90a, Hsp90b,
Grp94 and a-tubulin protein levels and expression of gp110 and gp140TrkAI in TrkAI transfectants (a) and total and tyrosine
phosphorylated TrkAIII (pTrkAIII) in TrkAIII transfectants (b).
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Discussion
In this study, we report important observations con-
cerning the interaction between Hsp90 chaperones and
effects of GA on the NB tumour-suppressor TrkAI
and its oncogenic alternative TrkAIII splice variant
in human NB cells. For the ﬁrst time, we characterize
TrkAI and TrkAIII as novel Hsp90 clients, report that
TrkAI is involved in GA-sensitive interactions with
Hsp90a and Hsp90b required for immature receptor ER
–export, maturation, cell surface translocation, stability
and ligand-dependent activation and that TrkAIII
exhibits GA-sensitive interactions with Hsp90a and
Hsp90b required for maintaining spontaneous intracellular
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activity and to a lesser extent stability. We show that
TrkAIII reduces NB cell sensitivity to GA-induced
growth inhibition and elimination, and we characterize a
novel TrkAIII-speciﬁc PNA inhibitor that counteracts
this effect. Our data implicate GA-sensitive interactions
with Hsp90 as potentially critical for TrkAI tumour
suppressor and TrkAIII oncogenic function in NB.
Hsp90 stabilization of cell surface TrkAI, suggested
by GA-induced loss of cell surface TrkAI immuno-
reactivity and gp140TrkAI protein expression, was
conﬁrmed by siRNA Hsp90a and Hsp90b knockdown,
which also induced gp140TrkAI loss and siRNA
Hsp90b knockdown, which induced loss of cell surface
TrkAI immunoreactivity. GA effect on gp140TrkAI was
reversed by MG-132 (Marques et al., 2004), indicating
lysosome/proteosome-mediated gp140TrkAI degrada-
tion. This presumably results from GA-induced inter-
nalization of inactive cell surface TrkAI, as described
earlier for degradation of internalized ligand-activated
TrkA (Geetha and Wooten, 2008). The differences in
time taken for GA and siRNAs to inﬂuence TrkA reﬂect
relatively immediate GA inhibition of Hsp90 catalytic
activity, but relatively slow siRNA knockdown of
Hsp90 expression in the absence of catalytic inhibition.
The clinically relevant GA-analogues 17-AAG and 17-
DMAG (Miyata, 2005) also induced lysosomal/proteo-
some-mediated gp140TrkAI degradation in stable
TrkAI transfectants, and GA also induced lysosome/
proteosome-mediated degradation of endogenous
gp140TrkA expressed by non-transfected SH-SY5Y
and IMR32 NB cells, conﬁrming an effect not restricted
to transfected TrkA.
TrkAI interaction with Hsp90 at the cell surface was
supported by overlapping cell surface TrkAI and
Hsp90a/b expression, TrkAI co-IP of Hsp90 from
puriﬁed membranes and reduced cell surface TrkAI
expression after siRNA Hsp90 knockdown, in TrkAI
transfectants. However, because of lack of adequate
mono-speciﬁc anti-Hsp90a and Hsp90b antibodies for
FACS and IF, we are unable to state whether Hsp90a,
in addition to Hsp90b, is also expressed at the SH-SY5Y
cell surface. Cell surface Hsp90 (a/b) expression was also
detected in pcDNA and TrkAIII transfectants, adding
SH-SY5Y cells to other tumour and normal cell types
that express cell surface Hsp90 (a/b) (Becker et al., 2004;
Sidera et al., 2004, 2008) and TrkAI to other cell surface
receptors that depend on interaction with Hsp90 for
stability (Vega and De Maio, 2003; Peng et al., 2005).
Mature cell surface gp140TrkA is synthesized
initially within the ER as the immature 110-kDa form
gp110TrkA, which contains a 30-kDa N-linked sugar
moiety (Martin-Zanca et al., 1989; Watson et al., 1999)
that is subsequently matured to gp140TrkA by carbo-
hydrate moiety modiﬁcation before cell surface trans-
location (this study; Jullien et al., 2002). GA and GA
analogues induced accumulation of intracellular
gp110TrkAI. This was not impaired by MG-132 and
was, therefore, independent of gp140TrkAI degrada-
tion, indicating that gp110TrkAI, unlike pg140TrkAI, is
not stabilized by a GA-sensitive interaction with Hsp90.
GA also increased gp110TrkAI ER retention, implicat-
ing Hsp90 in gp110TrkAI ER export, as a pre-requisite
for maturation and cell surface translocation (this study;
Jullien et al., 2002). In untreated TrkAI transfectants,
ER-associated gp110TrkAI bound Grp94, but not
Hsp90, suggesting that Grp94 rather than Hsp90
regulates ER export. However, this was not supported
by siRNA Grp-94 knockdown, which in contrast to
Hsp90a and Hsp90b knockdown did not inﬂuence
TrkAI expression. Hsp90 (a/b) may, therefore, regulate
TrkAI ER export with binding missed either by the
relatively low level of ER-associated TrkAI and/or
preferential interaction with gp140TrkAI. In any case,
GA disruption of TrkAI suggests that Hsp90 interacts
with this receptor at an early stage required for receptor
maturation and sorting, which is of relevance to the
pharmacological use of Hsp90 inhibitors.
Short-term pre-incubation with GA also attenuated
NGF-induced TrkAI tyrosine phosphorylation without
reducing gp140TrkAI. This was not reversed by
MG132, indicating independence from lysosome/pro-
teosome-mediated degradation, suggesting that Hsp90
facilitates ligand-mediated gp140TrkAI activation. This
adds to reports that Hsp90 interacts with the tk domains
of several kinases to regulate activity (Marcu et al.,
2002) and original characterization of GA as a tk
inhibitor (Marczin et al., 1993). The observation that
tk-loop tyrosine mutated muTrkAIII exhibited reduced
Hsp90 binding suggests that Hsp90 interacts with TrkA
tk-domain tyrosines required for TrkA tk activity, as
reported earlier for Hsp90 interaction with the ErbB2 tk
domain (Xu et al., 2001). We do not rule out, however,
Figure 9 TrkAIII tk activity regulates intracellular trafﬁcking. (a) Indirect IF comparison of intracellular TrkAIII and muTrkAIII
expression in respective stable transfected SH-SY5Y cells. (b) IP–western blots comparing total (TrkAIII), tyrosine phosphorylated
TrkAIII (pTrkAIII) and TrkAIII co-IP of Hsp90, calnexin and Grp78/BiP in whole cell extracts from TrkAIII and muTrkAIII SH-
SY5Y transfectants. (c) Western blots comparing the distribution of calnexin and GM130 in puriﬁed Histodense ultracentrifugation-
fractionated internal membranes puriﬁed from TrkAIII (upper left panels) and muTrkAIII stable SH-SY5Y transfectants (upper right
panels), plus IP–western blots (TrkAIII IP/western blot) demonstrating differences in the relative distribution of total (TrkAIII),
tyrosine phosphorylated TrkAIII (pTrkAIII) and differences in TrkAIII and muTrkAIII co-IP of Hsp90, Grp78/BiP and Calnexin in
Histodense ultracentrifugation-fractionated internal membranes from respective stable SH-SY5Y transfectants. (d) Comparative
western and IP–western blots demonstrating the distribution of GM130 and calnexin in Histodense ultracentrifugation-fractionated
internal membranes and differences in the distribution of non-phosphorylated (TrkAIII) and tyrosine phosphorylated TrkAIII
(pTrkAIII) in Histodense ultracentrifugation-fractionated internal membranes puriﬁed from TrkAIII SH-SY5Y transfectants treated
overnight with 100 nM CEP-701 (left panels) or with 1mM sodium orthovanadate (NaVO4) (right panels). (e) IP–western blots
demonstrating total (TrkAIII) and tyrosine phosphorylated TrkAIII (pTrkAIII) and the difference in TrkAIII co-IP of Hsp90 from
whole cell extracts from untreated TrkAIII SH-SY5Y transfectants (Con), TrkAIII SH-SY5Y transfectants treated overnight with
100 nM CEP-701 or 1mM sodium orthovanadate-treated (NaVO4).
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Figure 10 TrkAIII induces partial activation of the ER-stress response. (a) Reporter gene assays demonstrating signiﬁcantly elevated (*)
levels of constitutive transcriptional activity from the 5xATF6PoFLuc-GL3 reporter gene in TrkAIII SH-SY5Y transfectants compared
with pcDNA and TrkAI transfectants (Con), normalized for each cell line to background luciferase activity from the cfos-promoted
enhancer-less PoFLuc-GL3, plus the effect of 12h incubation of SH-SY5Y transfectants with 1mM GA on ATF6 transcriptional activity
(GA). (b) IP–western blots demonstrating increased constitutive expression of Grp78/BiP to Hsp90 and a-tubulin proteins in TrkAIII
compared with pcDNA and TrkAI SH-SY5Y transfectants. (c) RT–PCR demonstration of lack of constitutive alternative XBP-1 splicing in
pcDNA, TrkAI and TrkAIII SH-SY5Y transfectants (0 lane for each transfectant) with transient induction alternative XBP-1 splicing in
pcDNA, TrkAI and TrkAIII SH-SY5Y transfectants after treatment with 1mM GA for 3h, but not at later times, relative to GAPDH
mRNA expression. (d) Western and IP–western blots demonstrating the effect of treating pcDNA, TrkAIII and TrkAI SH-SY5Y
transfectants over a 12h time course with 1mM GA on Grp78/BiP, ATF6 (IP–western), Hsp90, Bcl-2 and a-tubulin protein expressed.
(e) Graphic representation of the above western blots demonstrating changes in Grp78/BiP to a-tubulin densitometric ratios (left) and Hsp90
to a-tubulin densitometric ratios (right) after treatment of pcDNA, TrkAI and TrkAIII SH-SY5Y transfectants with 1mM GA.
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that GA may interfere with NGF-TrkA ligation or
promote rapid internalization of non-degraded receptor
to account for this effect. Nevertheless, these data
indicate that Hsp90 is required for TrkAI cell surface
stability and ligand-dependent activation, identifying
Hsp90 as a critical component of TrkAI tumour-
suppressor activity in NB (Nakagawara et al., 1992;
Nakagawara, 2001).
In contrast to TrkAI, TrkAIII was not expressed at
the cell surface or as two distinct forms, indicating that
TrkAIII does not undergo carbohydrate moiety mod-
iﬁcation and implicating extracellular-domain N-linked
carbohydrates, omitted from TrkAIII, in gp140TrkAI
maturation and cell surface translocation (this study;
Watson et al., 1999; Jullien et al., 2002). The complete
absence of TrkAIII biotinylation in pulse-chase experi-
ments conﬁrms that intracellular TrkAIII accumulation
does not result from increased cell surface receptor
internalization or instability. Furthermore, cell surface
Hsp90a/b expression by all SH-SY5Y transfectants
indicates that intracellular TrkAIII accumulation does
not depend on lack of cell surface Hsp90. We are
investigating the possibility that cell surface Hsp90 may
exhibit a unique interaction with TrkAI extracellular-
domain sequence deleted from TrkAIII.
A requirement for GA-sensitive interaction with
Hsp90 for spontaneous intracellular TrkAIII activity
was suggested by GA and GA-analogue (17-AAG and
17-DMAG) inhibition of TrkAIII tyrosine phosphor-
ylation and reduction of TrkAIII levels and conﬁrmed
by siRNA Hsp90b and Hsp90a, but not Grp-94
knockdown, which also inhibited TrkAIII tyrosine
phosphorylation. However, in contrast to gp140TrkAI,
GA induced only low-level TrkAIII loss, indicating that
TrkAIII similar to gp110TrkAI is less dependent on
Hsp90 for stability, which bears similarity to GA
inhibition of Src tk activity in the absence of degrada-
tion (Bijlmakers and Marsh, 2000; Crevecoeur et al.,
2008). Limited GA-induced TrkAIII loss was reversed
by MG132 and was, therefore, lysosome/proteosome
mediated and was not restricted to phosphorylated
receptor, but also detected with non-phosphorylated
CEP-701-inhibited TrkAIII and muTrkAIII. In contrast
to transfected TrkAIII, however, GA did not reduce
endogenous TrkAIII levels in non-transfected SH-SY5Y
or IMR32 cells, indicating that Hsp90 stabilizes non-
phosphorylated transfected, but not endogenous
TrkAIII, which may relate to relative expression levels.
MG-132 alone did not inﬂuence TrkAIII expression or
tyrosine phosphorylation, indicating that spontaneously
active intracellular TrkAIII is not subject to the same
proteosome/lysosome-mediated degradation pathway as
internalized ligand-activated cell surface TrkAI (Geetha
and Wooten, 2008).
Potential involvement of phosphorylated tk-loop
tyrosines in Hsp90 binding, suggested by relatively high
level Hsp90 binding by tyrosine phosphorylated
TrkAIII compared with non-phosphorylated CEP-701-
inhibited TrkAIII and muTrkAIII, is supported by
reports that Hsp90 binds the ErbB2 receptor tk domain
(Xu et al., 2001). The possibility that this interaction not
only stabilizes TrkAIII tk –activity but also determines
TrkAIII intracellular distribution is supported by
observations that (a) TrkAIII exhibited tyrosine phos-
phorylation and Hsp90 binding in ER and non-ER
membranes; (b) GA and CEP-701 inhibited TrkAIII
tyrosine phosphorylation and promoted ER retention;
(c) non-phosphorylated muTrkAIII exhibited predomi-
nant ER retention and (d) sodium orthovanadate
stimulated TrkAIII tyrosine phosphorylation and trans-
location to non-ER membranes. This differs from
Hsp90 involvement in TrkAI ER export, maturation
and cell surface translocation, which occurs in the
absence of receptor tyrosine phosphorylation. This
implicates extracellular IG-C1 and mature extracellu-
lar-domain carbohydrates in regulating TrkAI ER
export and sorting, and preventing ligand-independent
activation, consistent with earlier reports (Watson et al.,
1999; Arevalo et al., 2000), with their omission from
TrkAIII altering intracellular distribution by promoting
intracellular accumulation, spontaneous activation and
ER quality control recognition. TrkAIII, muTrkAIII
and CEP-701-inhibited TrkAIII also exhibited low-level
GA-insensitive Hsp90 binding, indicating passive inter-
action with Hsp90 similar to that reported for citrate
synthase and MyoD (Shankovich et al., 1992; Jakob
et al., 1995; Scheibel et al., 1998).
ER quality control recognition of TrkAIII, conﬁrmed
by high level ER retention and constitutive Grp78/Bip,
Hsp90 and calnexin binding, suggests that TrkAIII may
induce ER stress. This was conﬁrmed by constitutive
ATF-6 transcription factor activity, ATF6 processing
and elevated ER-stress chaperone Grp78/Bip expres-
sion, which characterize the ER-stress response (Schro-
der, 2008), in TrkAIII, but not pcDNA or TrkAI
transfectants. TrkAIII transfectants did not, however,
exhibit alternative XBP-1 splicing, indicating that ER
perturbation is below the threshold required for full ER-
stress response activation (Schroder, 2008). Neverthe-
less, this provides a novel mechanism, in addition to
constitutive PI3K/Akt/NF-kB activation (Tacconelli
et al., 2004), through which TrkAIII may increase NB
cell stress resistance.
TrkAIII SH-SY5Y transfectants exhibit increased
stress resistance (Tacconelli et al., 2004) and also
reduced sensitivity to GA-induced inhibition of prolif-
eration and survival, compared with pcDNA and
TrkAIII transfectants. This was conﬁrmed as TrkAIII
mediated by PNA inhibition of TrkAIII expression,
which signiﬁcantly restored TrkAIII transfectant sensi-
tivity to GA-induced growth inhibition. Potential clonal
differences in GA sensitivity were also ruled out by
transient TrkAIII expression, which signiﬁcantly in-
creased survival of pcDNA and TrkAI stable transfec-
tant in the presence of GA. The reduced GA sensitivity
of TrkAIII transfectants was not, however, associated
with neuronal differentiation, earlier reported to reduce
GA sensitivity of SH-SY5Y cells (Shen et al., 2007).
Differential TrkAI and TrkAIII transfectant sensitiv-
ity to GA resulted in GA selection of TrkAIII
transfectants from co-culture with TrkAI transfectants,
conﬁrming TrkAIII negative impact on GA-induced NB
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cell eradication and adding TrkAIII to other oncogenes,
including ERGFR, which decrease tumour cell GA
sensitivity (Theodoraki et al., 2007; Puyo et al., 2008).
This, combined with TrkAIII re-phosphorylation after
GA removal, provides a potential mechanism for post
GA therapeutic relapse. Potential mechanisms through
which TrkAIII reduces GA sensitivity, despite GA
inhibition of TrkAIII activity include (a) constitutive
activation of the anti-apoptotic PI3K/Akt/NF-kB path-
way (Tacconelli et al., 2004), which may offer initial
protection before GA inhibition of NF-kB activation
(Crevecoeur et al., 2008); (b) partial ER-stress response
activation and increased Grp78/BiP expression, both of
which protect against stress-induced apoptosis (Rao
et al., 2002; Schroder, 2008) and (c) GA induction of
Bcl-2 expression exclusively in TrkAIII transfectants,
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which may promote long-term survival in the presence
of GA, as Bcl-2 inhibits both GA and GA-analogue-
induced apoptosis (Nimmanapalli et al., 2003). We are
further investigating the possibility that TrkAIII may
modify the ER-stress response to promote survival.
In conclusion, we classify TrkAI and TrkAIII as
novel Hsp90a and Hsp90b clients involved in GA-
sensitive interactions critical for maintaining TrkAI
tumour suppressor and TrkAIII oncogenic function in
NB cells. We propose that TrkAIII reduces GA
sensitivity through partial activation and modiﬁcation
of the ER-stress response and that TrkAIII negative
impact on GA-induced eradication and re-activation on
GA removal provides a potential mechanism for post
GA-therapeutic relapse that can be counteracted by
TrkAIII-speciﬁc PNA. Finally, we caution that GA
destabilization of cell surface TrkAI may have unfore-
seen consequences for normal TrkA-dependent cellular
functions.
Materials and methods
Cell lines, reagents and antibodies
Cell lines, reagents and antibodies are detailed in Supplemen-
tary Materials.
TrkAIII adenoviral and the TrkAIII Y670/674/675F mutant
expression vectors
TrkAIII adenoviral expression vector was constructed by sub-
cloning TrkAIII cDNA complete with polyadenylation signal
(Tacconelli et al., 2004), through the Gateway entry vector
into the pAd/CMV/v5-DEST adenoviral expression system,
as directed by the manufacturer (Invitrogen, Carlsbad, CA,
USA). The pcDNA3.1 TrkAIII Y670/674/675F mutated
expression vector was constructed by PCR from TrkAIII
cDNA and sub-cloned into pcDNA3.1 expression vector, as
detailed in Supplementary Materials.
Metabolic labelling of TrkAI and TrkAIII
Pulse-chase metabolic TrkAI and TrkAIII labelling was
performed as described earlier (Jullien et al., 2002) and
detailed in Supplementary Materials.
Figure 11 TrkAIII reduces SH-SY5Y sensitivity to GA-induced growth inhibition. (a) Graphic representation of comparative 3 days
MTS proliferation assays of control (pcDNA), TrkAI and TrkAIII SH-SY5Y transfectants grown in the absence of GA (control) or
presence of 0.1 mM GA or 1.0mM GA in duplicated assays performed using six cultures per point. (b) Graphic representation of 3 days
MTS proliferation assays of pcDNA transfectants (left graph) and TrkAI transfectants (right graph) either sham transiently
transfected and grown in the absence of GA (control), sham transiently transfected and grown in the presence 1mM GA (GA),
transiently transfected with TrkAIII expression vector and grown in the absence of GA (TrkAIII) or transiently transfected with
TrkAIII expression vector and grown in the presence of 1 mM GA (TrkAIIIþGA) in duplicated assays performed using six cultures per
point. (c) Histogram of MTS survival assays demonstrating the percentage 48 h survival of pcDNA, TrkAI and TrkAIII SH-SY5Y
transfectants treated with GA treatment at the concentrations indicated in duplicated assays performed using six cultures per point.
(d) Histogram demonstrating comparative percentage levels of apoptosis in pcDNA, TrkAI and TrkAIII SH-SY5Y cultures grown for
48 h in the absence (Con) or presence of 0.1 mM GA in triplicate cultures per cell line. (e) IP–western blots demonstrating the effect of
treating TrkAI and TrkAIII SH-SY5Y transfectants with 10mM TrkAIII-PNA for 0, 3 and 7 days on TrkAI, TrkAIII and a-tubulin
(a-tub) expression. (f) Graphic representation of 3 days MTS proliferation assays comparing proliferation of untreated TrkAIII SH-
SY5Y transfectants (control), TrkAIII SH-SY5Y transfectants in the presence of 0.1 mM GA (GA 0.1mM) and 1.0 mM GA (GA 1.0mM)
compared with TrkAIII SH-SY5Y transfectants pre-treated for 7 days with 10mM TrkAIII-PNA, before MTS assay in the absence of
GA (PNA), in the presence of 0.1 mM GA plus 10 mM PNA (PNAþGA 0.1 mM) or 1.0mM GA plus 10mM PNA (PNAþGA 1.0mM).
Duplicate assays were performed using six independent cultures per point. Asterisks refer to signiﬁcant differences.
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Figure 12 GA-induces selection of TrkAIII transfectants from co-
culture with TrkAI transfectants. (a) Indirect IF demonstrating
differences in the pattern of TrkA I and TrkAIII immunoreactivity in
3 days untreated co-cultures of TrkAI and TrkAIII SH-SY5Y
transfectants (3 days untreated) or co-cultures grown in the presence
of 1mM GA (3 days GA) (* refers to a signiicant difference). (b)
Histogram demonstrating 3 days MTS assays of TrkAI and TrkAIII
SH-SY5Y transfectant co-cultures grown for 0 and 3 days in the
absence (untreated) or presence of 1mM GA (GA). (c) RT–PCR (left
panels) demonstrating relative TrkAI and TrkAIII mRNA expres-
sion in TrkAI and TrkAIII SH-SY5Y co-cultures grown for 3 days in
the absence of GA (Con) or presence of 1mM GA (GA) and (d)
IP/western blots (right panels) demonstrating relative levels of
gp140TrkAI, pg110TrkAI and TrkAIII in TrkAI and TrkAIII SH-
SY5Y transfectant co-cultures grown in the absence of GA (Con) or
in the presence of 1mM GA for 1 and 3 days.
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RT–PCR conditions and primers
Reverse transcription was performed using mRNA (1 mg) and
a Moloney Murine Leukaemia virus reverse transcriptase kit in
a ﬁnal volume of 20 ml for 45min at 42 1C, according to the
manufacturer (Life Technologies, Paisley, UK). RT reaction
aliquots (1 ml) were subjected to 35 cycles of PCR (1min at
94 1C, 1min at optimized annealing temperature and 2min at
72 1C) using speciﬁc primers for TrkA I/II, TrkAIII, Hsp90a,
Hsp90b, Grp94, NF-M, Neuro-D, XBP-1 and GAPDH, as
detailed in Supplementary Materials.
IP and western blots
IP and western blotting was performed using standard
techniques, as described in Supplementary Materials.
Histodense ultracentrifugation fractionation of internal cell
membranes
Histodense ultracentrifugation fractionation of intracellular
membranes was performed as described earlier (Yoshimura
et al., 2001) and detailed in Supplementary Materials.
siRNA Hsp90 knockdown
Accell SMART pool siRNAs were used to knockdown
Hsp90a, Hsp90b and Grp94 expression in stable TrkAI and
TrkAIII SH-SY5Y transfectants, as outlined by the manufac-
turer (Thermo Scientiﬁc/Dharmacon, Lafayette, CO, USA)
and described in Supplementary Materials.
MTS proliferation and survival assays
MTS proliferation and survival assays were performed, as
outlined by the manufacturer (Promega, Milan, Itlay) and
detailed in Supplementary Materials.
Apoptosis
Apoptosis was assayed by ﬂuorescence microscopic identiﬁca-
tion of condensed and/or fragmented Heochst 33258-stained
nuclei as a percentage of total nuclei. Brieﬂy, SH-SY5Y
transfectants (50 000 cells/ml) were plated onto Costar culture
slides and incubated for 48 h in either complete medium or
medium containing 0.1 mM GA. After incubation, cells were
ﬁxed overnight in 70% ethanol at 4 1C and stained with
Heochst 33258. Apoptotic cells exhibited nuclear condensation
and/or fragmentation associated with membrane blebbing.
FACS analysis
For non-permeabilized cells analysis, SH-SY5Y transfectants
detached in PBS/EDTA were resuspended in PBS, dispersed
into 12 75mm tubes (0.5 106 cells per tube), centrifuged
and incubated with 0.5mg of anti Hsp90a/b antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or 0.5 mg of
normal mouse IgG, in 100 ml PBS at 4 1C for 1 h. After washing
with PBS, cells were incubated with FITC-conjugated goat
anti mouse IgG (Sigma, St Louis, MO, USA, diluted 1:128 in
PBS) at 4 1C for 45min, washed in PBS and resuspended in
500 ml PBS for analysis in an FACSCAN analyser (Becton
Dickinson, San Jose, CA, USA).
TrkAIII PNA synthesis
Fmoc (Bhoc) synthesis and HPLC puriﬁcation of the PNA
KKAA-TrkAIII (KKAA)4-GGCCGGGACACA are detailed
in Supplementary Materials.
Luciferase reporter assay
Reporter gene assays were performed in stable SH-SY5Y
transfectants transfected with either the 5xATF-PoFluc-GL3
reporter gene construct (Wang et al., 2000) or minimal cfos-
promoter enhancer-less PoFLuc-GL3, as detailed in Supple-
mentary Materials.
Statistical analysis
The results were compared using Student’s t-test and
considered statistically signiﬁcant at P-values of o0.05.
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